All In Biotech

Drug Trial Radar · NCT01303783

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Apr 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,381 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,381

Actual

Start

Apr 2011

Primary completion

May 2012

Study completion May 2012

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Feb 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the blood pressure lowering responses of various dose combinations of nifedipine GITS and candesartan as compared to treatment with each component on their own (monotherapy) and placebo (a look-alike tablet without active ingredient). The drugs - nifedipine GITS and candesartan - which are being investigated are currently approved for use in patients with essential hypertension alone or together with other antihypertensive drugs (combination therapy), but the optimal dose of nifedipine GITS and candesartan used together in the treatment of essential hypertension has not been established yet. In this study patients will be treated with various doses of nifedipine GITS and/or candesartan or placebo. These different regimens will be administered once a day and will be assessed based on their blood pressure lowering effects (mean sitting diastolic blood pressure) in subjects with mild to moderate essential hypertension.

Conditions

  • Hypertension, Essential

Interventions

  • Candesartan cilexetil (Atacand), 4 mgDrug

    4 mg of candesartan as capsule

  • Candesartan cilexetil (Atacand), 8 mgDrug

    8 mg candesartan as capsule

  • Nifedipine GITS (Adalat, BAYA1040), 20 mgDrug

    20 mg nifedipine as tablet

  • Nifedipine GITS (Adalat, BAYA1040), 30 mgDrug

    30 mg nifedipine as tablet

  • Nifedipine GITS (Adalat, BAYA1040), 60 mgDrug

    60 mg nifedipine as tablet

  • PlaceboDrug

    3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses

  • Candesartan cilexetil (Atacand), 16 mgDrug

    16 mg of candesartan as capsule

  • Candesartan cilexetil (Atacand), 32 mgDrug

    32 mg of candesartan as capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy variable is the change from baseline in mean seated diastolic blood pressure (MSDBP) at Week 8Time frame: Baseline taken at Visit 1; primary outcome variable assesed at 8 weeks

Locations

157 sites in 13 countries. Site status is shown where the registry gives one.

  • Site not named

    Mobile, Alabama

  • Site not named

    Los Angeles, California

  • Site not named

    Coral Gables, Florida

  • Site not named

    Deerfield Beach, Florida

  • Site not named

    Deerfield Beach, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Valparaiso, Indiana

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Harrisburg, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Salisbury, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Greenville, South Carolina

  • Site not named

    Mt. Pleasant, South Carolina

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Kenosha, Wisconsin

  • Site not named

    Bahía Blanca, Buenos Aires, Argentina

  • Site not named

    Quilmes, Buenos Aires, Argentina

  • Site not named

    Zárate, Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Córdoba, Córdoba Province, Argentina

  • Site not named

    Córdoba, Córdoba Province, Argentina

  • Site not named

    Corrientes, Corrientes Province, Argentina

  • Site not named

    Rosario, Santa Fe Province, Argentina

  • Site not named

    Santa Fe, Santa Fe Province, Argentina

  • Site not named

    De Pinte, Belgium

  • Site not named

    Deurne, Belgium

  • Site not named

    Ham, Belgium

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.